RESEARCH
www.commprac.com
ISSN 1462 2815

EHRLICH ASCITES CARCINOMA: A COMPREHENSIVE REVIEW OF PATHOGENESIS, PROGRESSION, AND THERAPEUTIC STRATEGIES

Sneha Sree S [1], Thangaraj Aravindan [2], Manikandan S [3], Taniya M [4] and K M Sundaram [5]*

[1,2,3,4,5] Biomedical Research Unit and Lab Animal Centre (BRULAC), Department of Anatomy, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical science (SIMATS), Saveetha University, Poonamalle High Road, Velappanchavadi, Chennai.
*Corresponding Author Email: meenakshisundaram.sdc@saveetha.com

DOI: 10.5281/zenodo.11083517

Abstract

This comprehensive review delves into the intricate landscape of Ehrlich Ascites Carcinoma (EAC), offering insights into its pathogenesis, progression, and therapeutic strategies. Originating from mouse mammary carcinoma cells, EAC serves as a valuable experimental model in cancer research, facilitating the exploration of various facets of cancer biology. Recent advancements have shed light on the molecular mechanisms underpinning EAC development, revealing key pathways such as angiogenesis, inflammation, and immune evasion as central players in tumor progression. Angiogenesis, orchestrated by factors like vascular endothelial growth factor (VEGF), drives tumor growth and dissemination, presenting promising targets for therapeutic intervention. Similarly, chronic inflammation, characterized by pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), fuels EAC progression by stimulating cell proliferation and angiogenesis. Strategies aimed at modulating inflammatory pathways offer potential avenues for inhibiting tumor growth and enhancing treatment efficacy. Moreover, immune evasion mechanisms employed by EAC, including the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), contribute to tumor immune escape, highlighting the importance of reprogramming the tumor immune microenvironment. Immunotherapeutic approaches, such as immune checkpoint blockade and adoptive cell therapy, hold promise for bolstering antitumor immune responses and restraining EAC progression. Additionally, combinatorial strategies integrating multiple therapeutic modalities present opportunities for synergistically improving treatment outcomes. Overall, this review provides a comprehensive overview of EAC, synthesizing insights from recent literature to guide future research endeavors and clinical interventions, ultimately aiming to advance our understanding and management of this aggressive malignancy.

Keywords: Ehrlich Ascites Carcinoma, Pathogenesis Progression, Therapeutic Strategies, Angiogenesis, Inflammation, Immunotherapy.

INTRODUCTION

Ehrlich ascites carcinoma (EAC) is a well-established experimental model in cancer research, originating from mouse mammary carcinoma cells and providing a crucial platform to explore diverse aspects of cancer biology (Holen, Speirs, Morrissey, & Blyth, 2017). Recent advancements have unveiled significant insights into the molecular mechanisms driving EAC development, revealing novel targets for therapeutic intervention. This review aims to provide a comprehensive overview of EAC, spanning its pathogenesis, progression, and therapeutic modalities, drawing from contemporary literature. EAC arises from the transplantation of Ehrlich tumor cells into the peritoneal cavity of mice, rapidly proliferating within the ascitic fluid and creating a tumor mass characterized by a highly angiogenic and immunosuppressive microenvironment (Abd Eldaim, Tousson, El Sayed, Abd Elmaksoud, & Ahmed, 2021). Key molecular pathways implicated in EAC pathogenesis include angiogenesis, inflammation, and immune evasion.

Angiogenesis, crucial for tumor growth and dissemination, is regulated by factors such as vascular endothelial growth factor (VEGF) and its receptors, offering potential targets for therapeutic intervention. Chronic inflammation, typified by the sustained activation of pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), promotes tumor growth and metastasis by stimulating cell proliferation, angiogenesis, and invasion (Melincovici et al., 2018). Strategies aimed at mitigating inflammation or targeting inflammatory pathways present viable approaches for inhibiting EAC progression and enhancing treatment efficacy.

Immune evasion mechanisms employed by EAC, including the recruitment of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), create an immunosuppressive microenvironment conducive to tumor survival and growth (Lin, Karakasheva, Hicks, Bass, & Rustgi, 2016). Reprogramming the tumor immune microenvironment through immune checkpoint blockade and adoptive cell therapy holds promise for augmenting antitumor immune responses and restraining EAC progression.

Therapeutic modalities for EAC encompass chemotherapy, targeted therapy, immunotherapy, and combinatorial strategies. While chemotherapy remains a cornerstone, its efficacy is limited by drug resistance and toxicity. Targeted therapy and immunotherapy offer more precise and promising approaches, with combinatorial strategies showing potential for synergistically enhancing treatment efficacy and overcoming resistance. This review aims to provide a comprehensive overview of the pathogenesis, progression, and therapeutic strategies for Ehrlich ascites carcinoma, incorporating recent literature findings (Yu et al., 2019).

Recent Advances in Pathogenesis and Progression

Recent years have seen substantial progress in unraveling the molecular mechanisms driving the development of Ehrlich Ascites Carcinoma (EAC).

Key pathways implicated in EAC pathogenesis encompass angiogenesis, inflammation, and immune evasion. Angiogenesis, the formation of new blood vessels, is pivotal for sustaining tumor growth and dissemination (Zhang et al., 2023). Central to this process is the dysregulation of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and its receptors. Inflammation, a hallmark of cancer, fuels EAC progression through the sustained activation of pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), promoting tumor cell proliferation, angiogenesis, and invasion (Varshan & Prathap, 2022). Additionally, immune evasion mechanisms are exploited by EAC to evade immune surveillance and foster tumor growth (Mosaffa, Kalalinia, Lage, Afshari, & Behravan, 2012).

This involves the creation of an immunosuppressive microenvironment orchestrated by the recruitment of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). Together, these pathways contribute to the aggressive nature of EAC and offer potential targets for therapeutic intervention. Understanding the intricate interplay between angiogenesis, inflammation, and immune evasion in EAC pathogenesis is crucial for developing effective treatment strategies to combat this malignancy and improve patient outcomes (Mailloux & Young, 2008).

Angiogenesis

Angiogenesis, the process of new blood vessel formation, emerges as a hallmark of tumor progression, prominently exemplified in Ehrlich Ascites Carcinoma (EAC). EAC, originating from the transplantation of Ehrlich tumor cells into the peritoneal cavity of mice, swiftly proliferates within the ascitic fluid, thereby creating an environment ripe for angiogenesis. The tumor microenvironment of EAC is characterized by heightened angiogenic activity, driven by a myriad of pro-angiogenic factors and signaling pathways. Among these, vascular endothelial growth factor (VEGF) stands out as a master regulator of angiogenesis, orchestrating the sprouting of new blood vessels to sustain tumor growth and dissemination (Yasuhara, Shingo, & Date, 2004). In EAC, VEGF and its cognate receptors are overexpressed, fueling the angiogenic switch and facilitating the formation of a dense vascular network within the tumor microenvironment. This neovascularization not only ensures an adequate supply of oxygen and nutrients to the burgeoning tumor but also provides a conduit for tumor cells to intravasate into the circulation and disseminate to distant sites. Recent studies have elucidated the intricate signaling cascades mediated by VEGF, uncovering potential therapeutic targets for disrupting tumor angiogenesis in EAC (Parveen et al., 2019).

Strategies aimed at inhibiting VEGF signaling pathways, such as VEGF receptor tyrosine kinase inhibitors and anti-VEGF monoclonal antibodies, have shown promising results in preclinical models, underscoring their potential as therapeutic avenues for curbing tumor angiogenesis and impeding disease progression in EAC (Prathap & Lakshmanan, 2022). Moreover, the integration of anti-angiogenic agents with conventional chemotherapeutic regimens holds promise for synergistically enhancing treatment efficacy and prolonging survival in patients with EAC.

Despite significant advancements in our understanding of angiogenesis in EAC, challenges persist in translating preclinical findings into clinical practice. Further research endeavors aimed at deciphering the complex interplay between angiogenic factors, elucidating mechanisms of resistance to anti-angiogenic therapy, and identifying predictive biomarkers of treatment response are warranted. By unraveling the intricacies of tumor angiogenesis in EAC, we can harness this knowledge to develop more effective therapeutic strategies for combating this aggressive malignancy and improving clinical outcomes for patients (Hegde, Wallin, & Mancao, 2018).

Ehrlich Ascites Carcinoma (EAC) represents an intriguing experimental model for investigating the intricate interplay between inflammation and cancer. Emerging from the transplantation of Ehrlich tumor cells into the peritoneal cavity of mice, EAC swiftly proliferates within the ascitic fluid, culminating in the formation of a tumor mass characterized by a highly angiogenic and immunosuppressive microenvironment (Justo, Silva, & Queiroz, 2001). In recent years, substantial evidence has highlighted the integral role of inflammation in driving EAC progression.

Chronic inflammation, typified by the sustained activation of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), perpetuates a milieu conducive to tumor growth and dissemination (USHANTHIKA & MOHANRAJ, 2020). These cytokines orchestrate a plethora of downstream signaling cascades, fueling tumor cell proliferation, angiogenesis, and invasion while simultaneously subverting antitumor immune responses. Moreover, the tumor

microenvironment in EAC is replete with various immunosuppressive cell populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), which collectively contribute to immune evasion and tumor immune escape. Strategies aimed at modulating the inflammatory milieu hold promise for attenuating EAC progression and potentiating the efficacy of conventional therapies (Zheng & Ma, 2022).

Recent advancements in this field have elucidated novel targets for intervention, ranging from cytokine blockade to inhibition of inflammatory signaling pathways. Furthermore, the integration of immunomodulatory agents such as immune checkpoint inhibitors and adoptive cell therapy offers new avenues for enhancing antitumor immune responses and improving treatment outcomes in EAC (Kubli, Berger, Araujo, Siu, & Mak, 2021).

The intricate interplay between inflammation and EAC pathogenesis underscores the multifaceted nature of cancer progression and presents opportunities for innovative therapeutic strategies aimed at disrupting inflammatory pathways and bolstering antitumor immunity. Future research endeavors aimed at deciphering the complex interactions between inflammation and cancer hold promise for guiding the development of more effective therapeutic approaches to combat EAC and other malignancies characterized by chronic inflammatory states.

Immune Evasion

Immune evasion stands as a pivotal mechanism exploited by tumors like Ehrlich Ascites Carcinoma (EAC) to subvert immune surveillance, thereby fostering their survival and progression. Within the intricate tumor microenvironment of EAC, a sophisticated network of immunosuppressive mechanisms is orchestrated, aimed at thwarting the host's immune response (Eskandari-Malayeri & Rezaei, 2022). EAC cultivates an immunosuppressive milieu characterized by the recruitment and activation of various immunosuppressive cell populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) (Mailloux & Young, 2008).

These immune cells exert multifaceted immunosuppressive functions, hampering the activity of effector immune cells and fostering an environment permissive to tumor growth and dissemination. Tregs, for instance, play a central role in maintaining immune homeostasis and tolerance by suppressing effector T cell responses. In the context of EAC, Tregs accumulate within the tumor microenvironment, where they dampen antitumor immune responses and promote tumor immune escape. Similarly, MDSCs, a heterogeneous population of immature myeloid cells, exert potent immunosuppressive effects by inhibiting the function of effector T cells and promoting regulatory T cell expansion (Prathap & Jayaraman, 2022b).

Furthermore, TAMs, a subset of tissue-resident macrophages, exhibit phenotypic plasticity and can adopt immunosuppressive phenotypes characterized by the expression of anti-inflammatory cytokines and immune checkpoint molecules. Collectively, these immunosuppressive mechanisms create a formidable barrier to effective antitumor immunity, allowing EAC to evade immune surveillance and flourish within the host organism (Hao et al., 2020). Strategies aimed at reprogramming the tumor immune microenvironment represent a promising approach for enhancing antitumor immune responses and improving treatment outcomes in EAC.

Recent preclinical studies have demonstrated the efficacy of various immunotherapeutic modalities, including immune checkpoint blockade and adoptive cell therapy, in bolstering antitumor immunity and restraining EAC progression (Xu, Sharma, Tuttle, & Pokharel, 2021). Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, unleash the antitumor activity of effector T cells by blocking inhibitory signals mediated by immune checkpoint molecules. Likewise, adoptive cell therapy harnesses the potent cytotoxicity of ex vivo expanded tumor-infiltrating lymphocytes (TILs) or genetically engineered T cells to eradicate tumor cells and overcome immune evasion mechanisms. Combinatorial approaches that integrate immunotherapy with conventional treatment modalities hold promise for enhancing treatment efficacy and prolonging survival in patients with EAC.

The elucidation of the complex interplay between immune evasion and EAC pathogenesis offers invaluable insights into the development of novel immunotherapeutic strategies for combating this aggressive malignancy (Ishii et al., 2010). Future research endeavors aimed at deciphering the molecular mechanisms underlying immune evasion in EAC and identifying predictive biomarkers of immunotherapy response will undoubtedly pave the way for personalized therapeutic interventions tailored to the individual patient's immune profile.

Exploration of Therapeutic Strategies

Therapeutic options for Ehrlich Ascites Carcinoma (EAC) include chemotherapy, targeted therapy, immunotherapy, and combination approaches. Chemotherapy, utilizing agents like cisplatin, doxorubicin, and paclitaxel, remains a cornerstone of EAC treatment, yet its efficacy is limited by the development of drug resistance and systemic toxicity (Xiao, Zhang, Zhao, Duan, & Yao, 2023). Targeted therapy offers a more precise approach by selectively inhibiting molecular targets critical for tumor growth and survival. Recent advancements have identified potential targets such as receptor tyrosine kinases (RTKs), the PI3K/AKT/mTOR pathway, and the Wnt/β-catenin pathway, providing opportunities for tailored treatment strategies (Colardo, Segatto, & Di Bartolomeo, 2021).

Immunotherapy, leveraging the body's immune system to recognize and eliminate tumor cells, has emerged as a promising modality for EAC (Prathap & Jayaraman, 2022a). Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, have shown efficacy in preclinical studies, offering new avenues for enhancing antitumor immune responses. Combinatorial approaches that integrate multiple modalities, including chemotherapy, targeted therapy, and immunotherapy, hold promise for synergistically improving treatment outcomes in EAC. However, challenges remain in overcoming drug resistance, minimizing toxicity, and identifying predictive biomarkers of treatment response. Continued research efforts are crucial for optimizing current therapeutic modalities and developing innovative strategies to overcome treatment resistance and improve outcomes for patients with EAC (Mohanraj, Varshini, & Somasundaram, 2021).

Targeted therapy holds considerable promise in the realm of Ehrlich Ascites Carcinoma (EAC), offering a precise and focused approach to combating this aggressive malignancy. EAC, stemming from the transplantation of Ehrlich tumor cells into the peritoneal cavity of mice, presents a complex landscape of molecular alterations ripe for targeted intervention (Rodríguez-Zhurbenko & Hernández Vázquez, 2024). The advent of targeted therapy has revolutionized cancer treatment

paradigms, enabling the selective inhibition of key molecular targets critical for tumor growth and survival. In the context of EAC, several molecular pathways have emerged as promising candidates for targeted intervention, including receptor tyrosine kinases (RTKs), the PI3K/AKT/mTOR pathway, and the Wnt/β-catenin pathway. RTKs, such as the epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), play pivotal roles in driving tumor progression by promoting cell proliferation, survival, and angiogenesis (Shahcheraghi et al., 2020). Dysregulation of the PI3K/AKT/mTOR pathway is frequently observed in EAC, contributing to aberrant cell growth and survival through its downstream effector pathways. Similarly, aberrant activation of the Wnt/β-catenin pathway is implicated in EAC pathogenesis, driving tumor cell proliferation, invasion, and metastasis.

Targeted inhibitors against these pathways have shown promising results in preclinical models of EAC, demonstrating potent antitumor activity and inhibiting tumor growth and dissemination. Moreover, the integration of targeted therapy with conventional treatment modalities such as chemotherapy or radiation therapy holds promise for synergistically enhancing treatment efficacy and overcoming therapeutic resistance in EAC (Abd El-Salam, El-Tanbouly, Bastos, & Metwaly, 2023). Despite these advancements, challenges persist in translating preclinical findings into clinical practice, including the emergence of drug resistance and the identification of predictive biomarkers of treatment response. Further research efforts aimed at elucidating the molecular mechanisms underlying EAC pathogenesis and therapeutic resistance are warranted. By harnessing the potential of targeted therapy, it may be possible to develop more effective treatment strategies for EAC, ultimately improving patient outcomes and quality of life (Durosini, Triberti, Savioni, Sebri, & Pravettoni, 2022).

Immunotherapy represents a promising frontier in the battle against Ehrlich Ascites Carcinoma (EAC), offering novel avenues for harnessing the immune system to combat this aggressive malignancy. EAC, arising from the transplantation of Ehrlich tumor cells into the peritoneal cavity of mice, orchestrates a complex interplay of immunosuppressive mechanisms aimed at evading immune surveillance and fostering tumor growth and dissemination. Within the tumor microenvironment of EAC, a myriad of immunosuppressive cell populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), conspire to create an immunosuppressive milieu conducive to tumor progression (Mailloux & Young, 2008).

This immunosuppressive microenvironment poses a formidable barrier to effective antitumor immune responses, underscoring the need for innovative immunotherapeutic strategies. In recent years, immune checkpoint blockade has emerged as a promising approach for unleashing the antitumor potential of the immune system in EAC. Immune checkpoint inhibitors, such as anti-programmed cell death protein 1 (PD-1) and anti-programmed death-ligand 1 (PD-L1) antibodies, work by blocking inhibitory signals that suppress T cell activity, thereby enhancing the cytotoxicity of effector T cells against tumor cells (Homet Moreno & Ribas, 2015). Preclinical studies have demonstrated the efficacy of immune checkpoint blockade in restraining EAC progression and improving survival in murine models. Furthermore, combinatorial approaches that integrate immune checkpoint inhibitors with other immunomodulatory agents or conventional treatment modalities hold promise for enhancing treatment efficacy and overcoming therapeutic resistance in EAC.

Additionally, adoptive cell therapy (ACT) represents another innovative immunotherapeutic strategy with potential applicability in EAC. ACT involves the ex vivo expansion and reinfusion of autologous or allogeneic tumor-infiltrating lymphocytes (TILs) or genetically engineered T cells with enhanced antitumor activity. Preclinical studies have shown encouraging results with ACT in EAC models, highlighting its potential as a complementary therapeutic approach to augment antitumor immune responses (Kverneland et al., 2021). Despite these advancements, challenges remain in translating preclinical findings into clinical practice, including the identification of predictive biomarkers of immunotherapy response and strategies to overcome immune evasion mechanisms. Moreover, the development of novel immunotherapeutic agents and combination strategies tailored specifically to the unique immunological landscape of EAC is warranted. By harnessing the power of immunotherapy, it may be possible to unleash the full potential of the immune system to eradicate EAC and improve clinical outcomes for patients. Continued research efforts aimed at unraveling the complexities of the tumor-immune interface in EAC will be crucial for advancing the field of immunotherapy and realizing its full therapeutic potential in the fight against this devastating disease.

CONCLUSION

In conclusion, this comprehensive review underscores the multifaceted nature of Ehrlich Ascites Carcinoma (EAC), delineating its pathogenesis, progression, and therapeutic strategies. Through elucidating the pivotal roles of angiogenesis, inflammation, and immune evasion, alongside the exploration of targeted therapy, immunotherapy, and combinatorial approaches, significant strides have been made in understanding and addressing this aggressive malignancy. Leveraging insights gleaned from contemporary literature, this review provides a roadmap for future research endeavors and clinical interventions, offering hope for improved outcomes and enhanced treatment modalities in the battle against Ehrlich Ascites Carcinoma.

Reference

1) Abd El-Salam, M., El-Tanbouly, G., Bastos, J., & Metwaly, H. (2023). Suppression of VEGF and inflammatory cytokines, modulation of Annexin A1 and organ functions by galloylquinic acids in breast cancer model. *Scientific Reports, 13*(1), 12268.

2) Abd Eldaim, M. A., Tousson, E., El Sayed, I. E. T., Abd Elmaksoud, A. Z., & Ahmed, A. A. (2021). Ameliorative effects of 9-diaminoacridine derivative against Ehrlich ascites carcinoma–induced hepatorenal injury in mice. *Environmental Science and Pollution Research, 28*, 21835-21850.

3) Colardo, M., Segatto, M., & Di Bartolomeo, S. (2021). Targeting RTK-PI3K-mTOR axis in gliomas: An update. *International Journal of Molecular Sciences, 22*(9), 4899.

4) Durosini, I., Triberti, S., Savioni, L., Sebri, V., & Pravettoni, G. (2022). The role of emotion-related abilities in the quality of life of breast cancer survivors: a systematic review. *International Journal of Environmental Research and Public Health, 19*(19), 12704.

5) Eskandari-Malayeri, F., & Rezaei, M. (2022). Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. *Frontiers in immunology, 13*, 996145.

6) Hao, J., Li, M., Zhang, T., Yu, H., Liu, Y., Xue, Y., . . . Wang, S. (2020). Prognostic value of tumor-infiltrating lymphocytes differs depending on lymphocyte subsets in esophageal squamous cell carcinoma: an updated meta-analysis. *Frontiers in Oncology, 10*, 614.

7) Hegde, P. S., Wallin, J. J., & Mancao, C. (2018). *Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.* Paper presented at the Seminars in cancer biology.

8) Holen, I., Speirs, V., Morrissey, B., & Blyth, K. (2017). In vivo models in breast cancer research: progress, challenges and future directions. *Disease models & mechanisms, 10*(4), 359-371.

9) Homet Moreno, B., & Ribas, A. (2015). Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. *British journal of cancer, 112*(9), 1421-1427.

10) Ishii, T., Ishida, T., Utsunomiya, A., Inagaki, A., Yano, H., Komatsu, H., . . . Akinaga, S. (2010). Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. *Clinical Cancer Research, 16*(5), 1520-1531.

11) Justo, G. Z., Silva, M. R., & Queiroz, M. L. (2001). Effects of the green algae Chlorella vulgaris on the response of the host hematopoietic system to intraperitoneal Ehrlich ascites tumor transplantation in mice. *Immunopharmacology and Immunotoxicology, 23*(1), 119-132.

12) Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021). Beyond immune checkpoint blockade: emerging immunological strategies. *Nature reviews Drug discovery, 20*(12), 899-919.

13) Kverneland, A. H., Chamberlain, C. A., Borch, T. H., Nielsen, M., Mørk, S. K., Kjeldsen, J. W., . . . Yde, C. W. (2021). Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. *Journal for immunotherapy of cancer, 9*(10).

14) Lin, E. W., Karakasheva, T. A., Hicks, P. D., Bass, A. J., & Rustgi, A. K. (2016). The tumor microenvironment in esophageal cancer. *Oncogene, 35*(41), 5337-5349.

15) Mailloux, A. W., & Young, M. R. I. (2008). Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) produce CCL22 which selectively recruits regulatory T-cells (Tregs) to the tumor microenvironment. In: Wiley Online Library.

16) Melincovici, C. S., Boşca, A. B., Şuşman, S., Mărginean, M., Mihu, C., Istrate, M., . . . Mihu, C. M. (2018). Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. *Rom J Morphol Embryol, 59*(2), 455-467.

17) Mohanraj, K. G., Varshini, V., & Somasundaram, J. (2021). Knowledge and Awareness On The Association Between Higher Body Mass Index and Plantar Fasciitis Among Chennain Population-A Survey. *Int J Dentistry Oral Sci, 8*(03), 1957-1962.

18) Mosaffa, F., Kalalinia, F., Lage, H., Afshari, J. T., & Behravan, J. (2012). Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. *Molecular and cellular biochemistry, 363*, 385-393.

19) Parveen, A., Subedi, L., Kim, H. W., Khan, Z., Zahra, Z., Farooqi, M. Q., & Kim, S. Y. (2019). Phytochemicals targeting VEGF and VEGF-related multifactors as anticancer therapy. *Journal of clinical medicine, 8*(3), 350.

20) Prathap, L., & Jayaraman, S. (2022a). Anti proliferative effect of endogenous dopamine replica in human lung cancer cells (A549) via Pi3k and Akt signalling molecules. *Journal of Pharmaceutical Negative Results*, 1380-1386.

21) Prathap, L., & Jayaraman, S. (2022b). Identification of Endogenous Superoxide Dismutase as a Potential Inhibitor for Pi3k/Akt Signaling In Colorectal Cancer-A Molecular Docking Study. *Journal of Pharmaceutical Negative Results*, 1374-1379.

22) Prathap, L., & Lakshmanan, G. (2022). Evaluation of incidence of various types of coronoid process in South Indian population. *Journal of Pharmaceutical Negative Results*, 1387-1390.

23) Rodríguez-Zhurbenko, N., & Hernández Vázquez, A. M. (2024). The Role Of B-1 Cells In Cancer Progression And Anti-Tumor Immunity. *Frontiers in immunology, 15*, 1363176.

24) Shahcheraghi, S. H., Tchokonte-Nana, V., Lotfi, M., Lotfi, M., Ghorbani, A., & Sadeghnia, H. R. (2020). Wnt/beta-catenin and PI3K/Akt/mTOR signaling pathways in glioblastoma: two main targets for drug design: a review. *Current Pharmaceutical Design, 26*(15), 1729-1741.

25) USHANTHIKA, T., & MOHANRAJ, K. G. (2020). Knowledge, Awareness and Risk Factors of Smartphone Addiction in Young Adult Population. *International Journal of Pharmaceutical Research (09752366), 12*(3).

26) Varshan, I., & Prathap, L. (2022). Evaluation of mandibular condylar morphology using orthopantomogram in South Indian population. *Journal of Advanced Pharmaceutical Technology & Research, 13*(Suppl 2), S530-S533.

27) Xiao, Q., Zhang, Y., Zhao, A., Duan, Z., & Yao, J. (2023). Application and development of nanomaterials in the diagnosis and treatment of esophageal cancer. *Frontiers in Bioengineering and Biotechnology, 11*.

28) Xu, S., Sharma, U. C., Tuttle, C., & Pokharel, S. (2021). Immune checkpoint inhibitors: cardiotoxicity in pre-clinical models and clinical studies. *Frontiers in Cardiovascular Medicine, 8*, 619650.

29) Yasuhara, T., Shingo, T., & Date, I. (2004). The potential role of vascular endothelial growth factor in the central nervous system. *Reviews in the neurosciences, 15*(4), 293-307.

30) Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019). Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. *Frontiers in immunology, 10*, 431246.

31) Zhang, J., Dong, Y., Di, S., Xie, S., Fan, B., & Gong, T. (2023). Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications. *Biomedicine & Pharmacotherapy, 167*, 115610.

32) Zheng, R., & Ma, J. (2022). Immunotherapeutic implications of toll-like receptors activation in tumor microenvironment. *Pharmaceutics, 14*(11), 2285.